QUOTE AND NEWS
FierceBiotech  Jun 15  Comment 
Termeer and Westphal out as Verastem looks to end losing streak badams Wed, 06/15/2016 - 07:24
SeekingAlpha  May 9  Comment 
Benzinga  Mar 30  Comment 
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of preclinical data by the Company's scientific collaborator David G. DeNardo, PhD, Assistant Professor of Medicine,...
SeekingAlpha  Mar 3  Comment 
newratings.com  Mar 3  Comment 
NEW YORK CITY (dpa-AFX) - German drug maker Merck KgaA (MKGAY.PK), Pfizer Inc. (PFE) and Verastem Inc. (VSTM) said they have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in...
SeekingAlpha  Mar 3  Comment 
Benzinga  Jan 6  Comment 
Verastem, Inc. (NASDAQ: VSTM) today announced the initiation of a Phase 1 dose-escalation study at Washington University to evaluate Verastem's FAK inhibitor VS-6063 in combination with Merck's PD-1 inhibitor pembrolizumab and...
SeekingAlpha  Nov 9  Comment 




 

Verastem (NASDAQ:VSTM) is a biopharmaceutical company which is developing small moleculre drugs to target cancer stem cells. The company believes that cancer stem cells are a key reason to the recurrence of tumors. These cells are resistant to chemotherapy and other cancer therapies. Verastem's drug will use small molecule compounds to directly target these cancer stem cells. [1]

Business Overview

Verastem is a prerevenue company. For the nine months ended in September of 2011, the company reported a net loss of $8M.[2]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on January 26, 2012. The company offered 5.5M shares each for $10. This was within the $9-$11 initial price range. The deal raised a total of $55M. The lead mangers of the deal were UBS and Leerink Swann.[3]

Trends & Forces

A Prerevenue R&D

At the time of its IPO, Verastem was early in its drug development stage. As a result, the company will have to successfully discover, receive approval, and commercialize a drug based on the money it has. If it fails to do that, it will have to find some other way to generate a cash flow. Because a drug like the one Verastem plans to discover has never been commercialized it is unclear if it is possible or if the FDA would approve it.[4]

  1. VSTM S-1/A 2011 PROSPECTUS SUMMARY "Overiew" pg.1-2
  2. VSTM S-1/A 2011 PROSPECTUS SUMMARY "Selected financial data" pg.48
  3. Renaissance Capital - IPO Home "Verastem prices upsized IPO at $10 midpoint" Jan 26 2012
  4. VSTM S-1/A 2011 PROSPECTUS SUMMARY "Risk factors" pg.11
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki